Suven secures four product patents in Australia, Eurasia, Israel and USA

Suven Life Sciences (Suven) has secured product patents in Australia, Eurasia, Israel and USA to its New Chemical Entities (NCE’s) for CNS therapy through mechanism of action - H3 Inverse agonist and these patents are valid until 2032, 2030, 2031 and 2032 respectively. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.

With these new patents, Suven has a total of twenty four granted patents from Australia, seventeen granted patents from Eurasia, nine granted patents from Israel and twenty four granted patents from USA. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.